Permanens Capital’s United Therapeutics UTHR Stock Holding History

Permanens Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,450	Closed	-$116K	–	140
2019 Q3	$116K	Sell	1,450 -4,700	-76%	-$379K	0.03%	39
2019 Q2	$480K	Buy	6,150 +150	+3%	+$14K	0.14%	29
2019 Q1	$704K	Buy	+6,000	New	+$699K	0.21%	24
2015 Q1	–	Sell	-600	Closed	-$78K	–	11
2014 Q4	$78K	Buy	+600	New	+$77.3K	0.08%	12

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Permanens Capital's UTHR Position: Q4 2019 in Review

Permanens Capital sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 1,450 shares — an estimated $116K sold.

Permanens Capital first reported a position in UTHR in Q4 2014 and held it in 4 quarters. The position peaked at $704K in Q1 2019. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

Permanens Capital reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
Permanens Capital sold 1,450 United Therapeutics shares in Q4 2019, an estimated $116K.
Permanens Capital first reported a position in United Therapeutics in Q4 2014 and held it in 4 quarters.
Permanens Capital's United Therapeutics position peaked at $704K in Q1 2019.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Permanens Capital's 13F filing for Q4 2019, filed 13 Feb 2020.